MARKET WIREYahoo • 3d ago
What Is Behind Liquidia's Lead Over Its Industry?For questions about this article or underlying research, email help@trefis.com.
Why INM Stock advanced +1.61% Today — RQD Quant Desk Flash
$1.63 +1.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.63
InMed Pharmaceuticals Inc. (INM) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $8.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.63 (+0.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INM)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY INM SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)
FRED Regime × Technicals: 60% of 52W Range • RSI-14 at 69.8 (BULLISH MOMENTUM)
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)
20D Institutional Volume Accumulation (±11.6% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.36-2.9% Next Q
39
Q2 (-2Q)Grade D$1.32+9.1% Next Q
42
Q3 (-1Q)Grade D$1.44+13.2% Next Q
44
CurrentGrade D$1.63-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INM Turnaround Squeeze
While INM currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.38) and Max Pain ($1.71) forces dealer call-delta covering toward $2.45.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INM Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INM Stock advanced +1.61% Today — RQD Quant Desk Flash
InMed Pharmaceuticals Inc. (INM) advanced +1.61% to $1.63, trading at 60% of its 52-week range ($0.57 – $2.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 60% of its 52-week range ($0.57 – $2.33) with RSI-14 at 69.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $1.63 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 34.5% gross margin and $0 annual free cash flow.
Live INM Headlines & Catalysts
CATALYSTYahoo • 5d ago
InMed Announces CVR Distribution Record Date in Connection with Proposed MergerVancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molec
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INM)
- ✓Walkthrough of INM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +126.39%⚡ TESTING RESISTANCE
2026-10-30O $1.55H $1.63L $1.51C $1.63VOL 36.7K
RES: $1.68SUP: $1.15SMA50: $1.38SMA200: $1.20
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INM)
Health Care Rank #426 of 1016
⚔️ PTN vs INM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INM vs. PTN, CMMB, MBRX, ENSC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, InMed Pharmaceuticals Inc. (INM) ranks #426 by composite RQD confidence (47/100, grade D) and #903 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, INM leads on earnings valuation at N/A trailing P/E, while INM leads on capital efficiency and profitability with -35.0% ROIC and 34.5% gross margin. INM currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INM
ACTIVE
InMed Pharmaceuticals Inc. | D | 47/100 | — | 34.5% | -35.0% | +1.61% | $8.9M | Benchmark Subject |
| PTN Palatin Technologies Inc. | D- | 38/100 | — | — | -35.0% | -3.33% | $8.8M | /ptn-vs-inm → |
| CMMB Chemomab Therapeutics Ltd. | D- | 38/100 | — | — | -35.0% | -0.91% | $8.8M | /cmmb-vs-inm → |
| MBRX Moleculin Biotech Inc. | D- | 43/100 | — | — | -35.0% | -0.29% | $9.2M | /mbrx-vs-inm → |
| ENSC Ensysce Biosciences Inc. | D- | 35/100 | — | — | -35.0% | -3.16% | $8.5M | /ensc-vs-inm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001728328In its most recent audited fiscal period (FY2025, filed 2025-06-30), InMed Pharmaceuticals Inc. (INM) reported GAAP revenue of $4.9M (+7.5% vs. FY2024 revenue of $4.6M , and +19.5% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-15.8% YoY). On the balance sheet, INM closed FY2025 with $11.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $4.9M | -$8.2M | -$8.1M | -$8.1M | $11.2M | — |
| FY2024 (FY) | 2024-06-30 | $4.6M | -$7.7M | -$7.0M | -$7.0M | $8.5M | — |
| FY2023 (FY) | 2023-06-30 | $4.1M | -$7.9M | -$7.3M | -$7.3M | — | — |
3. INM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, InMed Pharmaceuticals Inc. (NASDAQ: INM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.63 (+1.61% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INM ranks #426 in composite RQD confidence.
How does INM compare to PTN and CMMB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INM carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.5%, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and CMMB (Chemomab Therapeutics Ltd.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M). Among the 5-stock peer group, INM leads on earnings multiple (N/A) while INM leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INM?
Per INM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001728328), InMed Pharmaceuticals Inc. generated $4.9M in revenue (+7.5% YoY), -$8.2M in net income, and -$8.1M in free cash flow against $11.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INM trading relative to its 50-day, 200-day, and 52-week technical levels?
INM last traded at $1.63 (+1.61% on volume of 37,397 shares), positioning the stock +18.12% above its 50-day simple moving average ($1.38) and +35.83% above its 200-day simple moving average ($1.20). Across its 52-week range of $0.57 to $2.33, INM sits at the 60.2% percentile with a 14-day RSI of 69.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.6% ($1.44 to $1.82).
INM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INM stock moving today?
Why INM Stock advanced +1.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.